The development of noel virus vaccine is one step faster in our country

diarrhea caused by norovirus is endemic worldwide and endemic throughout the year, with mild infections mainly caused by vomiting, diarrhea and stomach pain. Children, the elderly and others have more severe symptoms, vomiting multiple times a day and even dehydration.known to have more than 30 genotypes, but 60% of human nonovirus outbreaks are caused by the GII.4 genotype. Human norovirus passes through inter-tissue antigens (HBGAs) on the surface of the intestinal mucous membrane; Usually A, B, O or Lewis antigens) bind to the cell surface. According to the U.S. Centers for Disease Control and Prevention (CDC), people infected with noel virus can excrete billions of noru virus particles, and only a few can make others sick. So far, however, there are no specific antibodies against noru viruses, because noru viruses mutate too quickly!researchers at the Chapel Hill Gillings School of Global Public Health at the University of North Carolina (UNC) have found an antibody that can widely suppress multiple noroviruses, an important step in the response to the terrible gastrointestinal flu.to design an effective noel virus vaccine, scientists need to identify a neus antibody, " he said. This antibody can respond to multiple strains, as well as future strains," said Baric, a professor of epidemiology at UNC and lead author of the study. Theteam first established a GII.4 antibody library that existed before and after immunization and selected several for table and structural analysis. The researchers found that the vaccinated antibodies were polarized and formed by previous norovirus infections, and that GII.4-specific antibodies blocked ancestral strains or antibodies that bind to different genotypes, and did not block the virus from entering the mating body. The researchers then identified the antibody identification bits.A1431 is a widely blocked neutral antibody whose binding points have been structurally determined. The study found that the antibody A1431 showed extensive blocking of GII.4 strains and was able to mesmloy all kinds of GII.4 endemic strains. The A1431 identifies conservative residues at the far end of the HBGAs binding region but can be accessed on assembled virus particles. Crystal structure analysis found that the A1431 with the shell protein P domain potentially provides a way to further improve the wide range and effectiveness of the antibody.This work describes for the first time the structure of the binding interaction between noel viruses and human antibodies, and demonstrates that infected and vaccine-induced antibodies can exhibit widespread blocking and saling against this common human pathogen.each of these antibody categories may contribute to vaccine-induced protection, and further research and in vivo models are needed to fully understand the interaction between antibody targets and physiological responses," the authors note. Inaddition to this, china's noel virus vaccine also came to the news. China's scientists independently developed, the international first noel virus four-price vaccine was officially approved for clinical research.The vaccine contains four recombinant virus-like particle antigens of the main genotypes of norovirus, which theoretically prevents 80 to 90 percent of norovirus infections and their causes of acute gastroenteritis, and is currently the most clinically licensed polycopic norovirus vaccine in the world.look forward to the completion of clinical research on this vaccine, to achieve the market, to overcome Noru! (Biological exploration)